Northwestern Mutual Wealth Management Co. Decreases Stock Holdings in Boston Scientific Corporation $BSX

Northwestern Mutual Wealth Management Co. trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 1.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 839,483 shares of the medical equipment provider’s stock after selling 14,862 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Boston Scientific were worth $35,829,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wedbush Securities Inc. raised its stake in shares of Boston Scientific by 16.8% in the second quarter. Wedbush Securities Inc. now owns 10,620 shares of the medical equipment provider’s stock worth $453,000 after buying an additional 1,530 shares during the period. Cullinan Associates Inc. grew its stake in shares of Boston Scientific by 2.1% during the 2nd quarter. Cullinan Associates Inc. now owns 24,299 shares of the medical equipment provider’s stock valued at $1,037,000 after acquiring an additional 500 shares during the period. Greenwood Capital Associates LLC purchased a new stake in Boston Scientific in the 2nd quarter worth approximately $3,351,000. New Mexico Educational Retirement Board increased its holdings in Boston Scientific by 7.3% in the 2nd quarter. New Mexico Educational Retirement Board now owns 73,762 shares of the medical equipment provider’s stock worth $3,148,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Royal London Asset Management Ltd. raised its position in shares of Boston Scientific by 13.1% during the 2nd quarter. Royal London Asset Management Ltd. now owns 753,076 shares of the medical equipment provider’s stock valued at $32,141,000 after purchasing an additional 87,185 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David C. Habiger purchased 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 194,522 shares of company stock worth $9,385,210 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Canaccord Genuity Group dropped their price objective on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Oppenheimer cut their price objective on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 27th. Finally, Truist Financial reduced their target price on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $48.05 on Wednesday. The firm has a fifty day simple moving average of $46.69 and a two-hundred day simple moving average of $56.17. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $69.64 billion, a P/E ratio of 19.45, a PEG ratio of 1.12 and a beta of 0.57.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the company earned $0.75 EPS. The business’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.